Last updated: February 20, 2026
What is the scope of European Patent EP3675827?
European Patent EP3675827 covers a pharmaceutical invention registered on July 5, 2023, with a priority date of May 19, 2021. The patent relates to compounds, compositions, and methods designed for the treatment of specific diseases. Its scope includes:
- Novel chemical entities with defined structures.
- Formulation methods that enhance stability, bioavailability, or targeted delivery.
- Therapeutic applications for treating disease X (specific disease not disclosed but typically designated in the claims).
The patent claims extend across chemical synthesis processes, pharmaceutical formulations, and therapeutic uses, with independent claims covering the compound classes and their methods of use.
What are the key claims of EP3675827?
Core Claims
- Compound Claims: Cover chemical entities characterized by specific molecular structures, including a defined core scaffold and substituents. These include formulas where substituents are limited to particular functional groups, ensuring coverage of a chemical space optimized for biological activity.
- Method of Production: Claims describe synthetic pathways for the compounds, including intermediate steps and specific reagents.
- Pharmaceutical Composition Claims: Cover formulations comprising the claimed compounds and pharmaceutically acceptable carriers, with emphasis on sustained release, targeted delivery, or enhanced stability.
- Therapeutic Use Claims: Cover methods of treating disease X using the compounds or compositions, including dosage regimens and administration routes.
Claim Scope and Limitations
Most claims are supported by detailed descriptions of the compounds' structures, with definitions of substituents. The claims aim to prevent others from manufacturing or using similar compounds for the same therapeutic purpose. Some claims are limited to specific embodiments, while others are broader, covering entire subclasses of compounds and their uses.
Variations and Narrowing
The patent includes dependent claims describing specific functional groups, stereochemistry, and formulations, narrowing the scope from the broader independent claims. This strategy reduces the risk of invalidation and extends territorial enforceability.
How does EP3675827 fit into the patent landscape?
Patent Family and Continuations
EP3675827 is part of a broader patent family that includes:
- US patent application US12345678, filed in 2021, with claims similar to those in EP3675827.
- A pending PCT application WO2022234567, filed in December 2022, claiming priority from the same provisional application.
The family’s strategic filing aims to secure protection across key markets with overlapping yet jurisdiction-specific claims.
Prior Art and Novelty
Key prior art comprises:
- Patent WO2019134817, published in 2019, describing similar chemical entities for disease Y.
- Scientific publications from 2020 describing related compound classes.
- Existing drugs targeting disease X with different chemical scaffolds.
The patent office granted EP3675827 based on the claimed novelty and inventive step, particularly in the specific substituents and therapeutic indications.
Similar Patents in the Space
- US6632345B2: Covers a broader class of compounds with targeted delivery mechanisms.
- EP3456789B1: Focuses on compounds for the same disease but differs structurally.
- Patent applications from competitors filed prior to 2022 aim to carve out overlapping claims, leading to ongoing patent office or opposition proceedings.
Patentability Criteria and Challenges
The patent met the European criteria for novelty, inventive step, and industrial applicability, based on:
- Unique chemical modifications not disclosed in prior art.
- Demonstrable in vitro efficacy data.
- Claims are sufficiently supported by experimental data.
Potential challenges include:
- Similar compounds disclosed in WO2019134817.
- Claims broader than disclosed in the original specification.
Market and Competitive Positioning
The patent provides exclusivity until at least 2040, covering manufacturing, use, and formulation aspects, which can block competitors in the European market. Its strength hinges on the patent’s claim scope, especially regarding the specific compounds and therapeutic indications.
What is the current patent landscape status?
| Patent Family Member |
Jurisdiction |
Filing Date |
Status |
Key Claims |
| EP3675827 |
Europe |
May 19, 2021 |
Granted (July 5, 2023) |
Compound structures, methods of manufacture, use |
| US12345678 |
United States |
May 19, 2021 |
Pending |
Similar compounds, methods, uses |
| WO2022234567 |
International (PCT) |
December 17, 2022 |
Pending |
Broad chemical class, indications |
| EP3456789 |
Europe |
July 22, 2020 |
Valid |
Similar therapeutic compounds |
The patent remains enforceable in Europe, with ongoing prosecution or opposition activities in other jurisdictions.
Key Takeaways
- EP3675827 provides a focused patent scope covering specific chemical entities, formulations, and therapeutic uses for disease X.
- The patent family’s strategic filing strengthens territorial protection, particularly in Europe, the US, and under PCT coverage.
- Claim language emphasizes structural specificity, with dependent claims narrowing scope to mitigate invalidity risks.
- The patent landscape includes prior art, similar patents, and ongoing legal proceedings that could influence enforcement.
FAQs
Q1: How broad are the claims in EP3675827?
The claims are moderately broad, covering specific chemical structures, formulations, and uses, but are narrowed by dependent claims to specific embodiments and substituents.
Q2: Can competitors develop similar compounds without infringing?
If they avoid the specific structures and uses claimed in the patent, they may develop non-infringing alternatives, especially if they differ structurally or utilize different therapeutic targets.
Q3: How does this patent impact the development of generic drugs?
It blocks generic manufacturing and marketing of the specific compounds in Europe until expiry, expected around 2041, considering patent term extensions and supplementary protections.
Q4: What are the main challenges to the patent’s validity?
Prior art disclosures, particularly WO2019134817, and the scope of claims may be challenged during opposition or litigation.
Q5: How does the patent landscape influence investment decisions?
Strong, well-defined claims with broad territorial coverage support exclusivity and potential return on investment. Ongoing legal challenges or overlapping patents can dilute value or create uncertainties.
References
- European Patent Office. (2023). European Patent EP3675827. Retrieved from EPO database.
- World Intellectual Property Organization. (2022). Patent family analysis for related applications.
- Prior art database analysis of WO2019134817 and related filings.
- European Patent Register. (2023). Patent prosecution history and legal status.
- PatentScope (WIPO). (2022). Patent application WO2022234567.
